Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply…
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
52,000-square-foot corporate headquarters in San Diego with R&D and GMP manufacturing center to open in 2022 Builds on current capability at Artiva’s partner, GC LabCell’s facility in Republic of Korea Custom-built GMP manufacturing center further expands Artiva’s leadership position in scaled, off-the-shelf NK and CAR-NK therapeutic manufacturing for treatment of solid and hematological cancers SAN […]
Elevation Oncology Announces Pricing of Initial Public Offering
J.P. Morgan Securities, Cowen, and SVB Leerink are acting as joint bookrunning managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
RayzeBio Secures $108 Million Series C Financing to Drive Forward Its Pipeline of Targeted Radiopharmaceuticals for Cancer
Neurogastrx Announces Agreement with Daewoong Pharmaceutical to Develop Fexuprazan for Treatment of Acid-Related GI Disorders in the U.S.
This agreement bolsters our mission to advance transformative therapeutics for GI disorders with significant unmet need and disease burden. The addition of fexuprazan to our pipeline, which already includes a late-stage investigational treatment for gastroparesis, further strengthens our potential to bring benefit to millions of patients with chronic and debilitating GI disorders,” said James O’Mara, Chief […]
NFlection Therapeutics’ NFX-179 Gel Demonstrates Safety and Significant Reduction in p-ERK, a Key Biomarker Driving Neurofibroma Tumor Growth, in Positive Data From a 28-Day Phase 2a Clinical Trial
– Trial designed to study 0.05%, 0.15% and 0.5% NFX-179 Gel in subjects with cutaneous neurofibromatosis type 1 (NF1) – NFX-179 Gel was well tolerated, with a safety profile similar to placebo (vehicle) – Primary endpoint achieved: NFX-179 Gel showed a dose-dependent suppression of phosphorylated ERK (p-ERK) in cutaneous neurofibroma (cNF) tumors, suppressing p-ERK by […]
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) May 14, 2021 18:25 ET| Source: Apellis Pharmaceuticals, Inc.
Attralus Therapeutics Appoints Mark Timney as CEO and Expands Leadership Team with New Executives
Attralus, backed by venBio Partners, recruits new leadership team to support advancement of its pipeline to bring transformational pan-amyloid removal therapies to the systemic amyloidosis field May 10, 2021 07:00 AM Eastern Daylight Time SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Attralus Therapeutics today announced the appointment of Mark Timney as the company’s Chief Executive Officer and a member […]
Impel NeuroPharma Announces Pricing of $80.0 Million Initial Public Offering
SEATTLE, April 22, 2021 (GLOBE NEWSWIRE) — Impel NeuroPharma, Inc. (Impel), a late-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, today announced the pricing of its initial public offering of 5,333,334 shares of its common stock at a price […]
Ventyx Biosciences Raises $114 Million Financing led by venBio Partners to Advance Diverse Pipeline of Immunology Programs
Proceeds to accelerate clinical development of best-in-class immunology programs and advance preclinical programs against novel drug targets with its prolific drug discovery engine ENCINITAS, Calif., March 9, 2021 /PRNewswire/ — Ventyx Biosciences, Inc. (“Ventyx”), a clinical-stage biotechnology company advancing a pipeline of immune modulators to treat inflammatory diseases and autoimmune disorders, today announced the completion of […]
